Inspire Biotherapeutics

Inspire has developed a lung tropic AAV gene therapy platform that has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. We are currently pursing initiation of a Proof-of-Concept clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can then be applied to Cystic Fibrosis and other monogenic lung diseases.